Proquazone ('Biarison') in osteoarthritis of the knee: a double-blind, dose comparison trial

Abstract

A double-blind study was carried out in 36 patients with osteoarthritis to evaluate the effectiveness and tolerance of 600 mg proquazone per day compared with 900 mg proquazone per day over a period of 3 months. The two groups showed statistically significant improvement in all the parameters investigated, thus confirming the potency of proquazone as an analgesic anti-inflammatory drug. The difference between the 2 groups, however, was not statistically significant, indicating an advantage for the lower daily dosage regimen over the high daily dosage regimen. Side-effects were more frequent and more severe in the high daily dosage group, demonstrating a further advantage of the lower daily dosage regimen.